IHE

What IHE does

IHE (The Swedish Institute for Health Economics, Institutet för Hälsoekonomi) is a private, for-profit health economic research and consulting institute founded in 1979 in Lund, Sweden, with a secondary office in Stockholm. It is owned through IHE Holding AB by its CEO, staff, and the Bengt Jönsson Foundation for Health Economic Research — a structure designed to preserve independence from any single commercial or governmental stakeholder. The firm employs roughly 30 multidisciplinary specialists (11 with PhDs, the majority with 10+ years of experience), several of whom hold joint appointments at Lund University and Karolinska Institutet.

IHE's core product set comprises two proprietary, externally validated diabetes simulation platforms — the IHE Diabetes Cohort Model (IHE-DCM, a Markov cohort model built in Excel) and the ECHO microsimulation (stochastic patient-level model programmed in R with Excel interfaces, available in separate T1DM and T2DM versions). Both have participated in the Mount Hood Diabetes Challenge since 2010 and are accepted for HTA submissions in Sweden, Norway, the UK, Scotland, Ireland, Canada, and Australia. Beyond these platforms, IHE offers health economic modelling, market access strategy, real-world evidence studies (leveraging Swedish and Nordic registries), and policy and preferences research across diabetes, oncology, neurology, dermatology, and rare diseases. It also runs an introductory health economics course programme, an annual two-day IHE Forum conference, a 200-member professional network, and an annual thesis scholarship with the Bengt Jönsson Foundation.

IHE generates revenue through five streams: project-based research and consulting fees from public-sector and life-science clients; course and training fees; conference attendance and sponsorship for the IHE Forum; licensing of IHE-DCM and ECHO; and grant-funded academic research from Swedish (Vinnova, IHI) and European (Horizon Europe, EU Cancer Mission) funders. Customer base exceeds 50 organisations across national authorities, pharmaceutical and med-tech companies, regional healthcare providers, academic partners, and patient organisations. GTM is sales-led and direct, with no intermediaries, and pricing is quote-based rather than publicly listed.

Name

IHE

Legal name

The Swedish Institute for Health Economics AB

Website

https://ihe.se

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

11–50 employees

Short description

IHE (The Swedish Institute for Health Economics) is a Lund, Sweden-based private health economics research and consulting firm serving public-sector, life-science, and academic clients in the Nordics and internationally. It monetises proprietary validated diabetes simulation models (IHE-DCM, ECHO), HEOR consulting, and grant-funded research.

Ownership category

akta.pro rank

Product category

Health Economics Research and Consulting

NAICS

Scientific Research and Development Services (5417), Research and Development in the Social Sciences and Humanities (54172)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Industry & Sector Research (Syndicated/Custom) (BPAHALAE)

Keywords

• Health economics research
• Health economic modeling
• Market access consulting
• Real-world evidence
• Cost-effectiveness analysis

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Research and Consultancy Services: IHE conducts both academic projects and consultancy work for life science companies (pharmaceutical and med tech), always on solid scientific ground. Revenue is generated through project fees for health economic analyses, modelling, market access support, and real-world evidence studies.
2. Courses and Training: IHE organizes introductory 2-day courses in health economics in Swedish each spring, an abbreviated 1-day version at IHE Forum, and tailored courses for specific client needs. Revenue generated through course fees.
3. IHE Forum Conference: Annual policy-oriented 2-day conference where healthcare stakeholders meet. Revenue generated through attendance fees and sponsorship.
4. Model Licensing: IHE's diabetes models (IHE-DCM and ECHO) can be licensed to skilled clients who want to conduct their own analyses. Revenue generated through licensing fees.
5. Grant-Based Academic Research: IHE participates in research projects funded by Swedish and European research financiers. Ongoing academic projects include I3LUNG (Horizon Europe), PREDEM (VINNOVA), PRIME-ROSE (EU Cancer Mission), PROMINENT (Innovative Health Initiative), StartCell (VINNOVA), Testbed Sweden for Precision Health in Cancer (VINNOVA), and Nordens välfärdscenter. These are funded through research grants rather than direct client fees.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

IHE conducts applied health-economics research and consulting for life-science companies, public-sector authorities, healthcare providers, and academia, developing proprietary simulation models (IHE-DCM and ECHO) for diabetes cost-effectiveness analysis and delivering market access, real-world evidence, and policy analysis services. The institute supplements project consulting with licensable models, introductory and tailored health-economics courses, and the annual IHE Forum conference. Revenue is generated primarily through project fees, model licensing, course fees, and conference attendance/sponsorship, alongside grant-funded academic research.

Product overview

IHE (The Swedish Institute for Health Economics) is a research institute providing health economic research and consulting services rather than a traditional software product company. Its core products consist of two specialized diabetes modeling platforms: the IHE Diabetes Cohort Model (IHE-DCM), a cohort-level Excel-based model, and the ECHO (Economic and Health Outcomes) Model, a more advanced microsimulation model programmed in R with Excel interfaces. The company also offers a portfolio of professional services including health economic modeling consulting, market access strategy support, real-world data analysis, and policy and preferences research. Educational offerings include introductory and tailored courses in health economics, the annual IHE Forum conference, and a student thesis scholarship program.

Differentiator

Problem solved

Functional benefit

Products and services

• IHE Diabetes Cohort Model (IHE-DCM) A cohort-level, Excel-based cost-effectiveness model designed for the long-term evaluation of interventions in both Type 1 and Type 2 diabetes, with annual-cycle Markov health states covering microvascular, macrovascular, and mortality outcomes. Supports comparison of up to 12 treatments in a single simulation, deterministic and probabilistic analyses, and can be licensed to skilled clients for in-house use.
• ECHO (Economic and Health Outcomes) Model A stochastic, patient-level microsimulation model for estimating long-term cost-effectiveness of treatments for Type 1 and Type 2 diabetes, with a separate ECHO-T2DM extension for obesity and pre-diabetes interventions. Programmed in R with Excel interfaces, used for early-stage decision making, market access, value story dissemination, and post-marketing evidence generation; available for licensing to clients.
• Health Economic Modelling Services Consulting service covering the development, validation, and adaptation of health-economics simulation models across diabetes, oncology, multiple sclerosis, Parkinson's disease, and other therapeutic areas. Supports budget impact analysis, guideline development, HTA cost-effectiveness analysis, and go/no-go pricing and licensing decisions for life-science clients.
• Market Access Services Strategic market access support for pharmaceutical and med-tech companies across the product lifecycle, including early pre-launch value assessment, registration and reimbursement activities, pricing and reimbursement submissions to HTA bodies, and market entry strategy for Nordic and international markets.
• Real-World Data and Evidence (RWE) Real-world data analysis services leveraging Sweden's national population registries, prescription registries, and disease-specific quality registries, with coverage extending across the Nordic region. Used for treatment-pattern studies, cost-of-illness analyses, epidemiology, and post-marketing evidence generation for life-science and public-sector clients.
• Policy and Preferences Analysis Policy research and consulting covering international and regional comparisons of health systems, patient preferences evaluation, payment model development, and healthcare efficiency analysis using DEA methodology. Used by public-sector authorities, life-science companies, and patient organisations to inform priority setting and policy decisions.
• Courses and Training in Health Economics Fee-based educational offering comprising an introductory 2-day course in health economics in Swedish held each spring, an abbreviated 1-day version at IHE Forum, and tailored courses on specific topics or therapeutic areas delivered in Swedish or English for individual client needs.
• IHE Forum Conference Annual 2-day policy-oriented conference where healthcare stakeholders convene to discuss current topics in health economics. Revenue is generated through attendance fees and sponsorship. The 2026 edition is scheduled for 3–4 September at Stadshallen in Lund.

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered minor and core.

• Nordic Welfare Centre (Nordens välfärdscenter)minorStrategic or Co-development Partner · 1 January 2026Project initiated and led by the Nordic Welfare Centre to gather knowledge and share examples of how economic estimations in public health are carried out in Nordic countries. IHE is responsible for carrying out the mappings and producing two reports: one on methods and models for economic estimations of modifiable risk factors, and one on health economic evaluations of preventive interventions implemented in the Nordic region. Reports will be published in spring 2027.
• Genomic Medicine Sweden (GMS) - Health Economics Working GroupminorStrategic or Co-development Partner · 1 January 2025GMS is a national initiative dedicated to the introduction and implementation of broad genomic sequencing for improved diagnostics and personalized treatment. IHE's Oskar Frisell serves as co-chair of the Health Economics Working Group within GMS since March 2025.
• PREDEM Consortium (Vinnova-funded)coreStrategic or Co-development Partner · 1 January 2023PREDEM is an innovation environment coordinated by Karolinska Institutet, funded by VINNOVA, bringing together regions, companies and organizations to introduce new tools for early detection, precision diagnostics, prevention and treatment of dementia. Partners include Karolinska Institutet, Karolinska University Hospital, IHE, Svenskt Demenscentrum, Demensförbundet, Region Skåne, Region Stockholm, Region Värmland, DigitalWell Arena, Geras Solutions AB, MindMore AB and Roche AB. IHE focuses on cost-effectiveness and payment models for prevention, diagnostics and treatment of dementia diseases.
• PRIME-ROSE Consortium (EU Cancer Mission)coreStrategic or Co-development Partner · 1 January 2023PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials) is a European research network for precision cancer medicine receiving EUR 6 million from the EU Cancer Mission. The consortium has 28 partners from 19 European countries. IHE contributes with pragmatic strategies for health economic evaluation of precision cancer medicine, including developing a conceptual modelling framework for cost-effectiveness of molecular target-driven treatment regimens.
• PROMINENT Consortium (Innovative Health Initiative)coreStrategic or Co-development Partner · 1 January 2023PROMINENT is a European collaboration creating a digital platform for precision medicine to improve diagnosis and treatment of neurodegenerative diseases and co-morbidities, funded through the Innovative Health Initiative (IHI). IHE leads the design, implementation and evaluation of a process to gather real-world evidence from the digital platform for evaluation of new technologies, with initial focus on disease-modifying therapies for Alzheimer's disease.
• StartCell Consortium (Vinnova-funded)minorStrategic or Co-development Partner · 1 January 2023StartCell is a Vinnova-funded project facilitating the development of high-quality commercially available induced pluripotent stem cells (iPSCs) for new cell therapies. Partners include Lund University, CCRM Nordic, Skövde University, Karolinska Institutet, KTH, LU Innovation, Region Skåne, Karolinska University Hospital and Takara Bio Europe. IHE leads work package 2 focusing on understanding production process costs and implications for value-based pricing of iPSC-derived therapies.
• Theranostics Trial Alliance Sweden (TTA Sweden)coreStrategic or Co-development Partner · 1 January 2023TTA Sweden is a Vinnova-funded national partnership for image-guided diagnostics and therapies with targeting radiopharmaceuticals, focused on precision oncology. Led by Theranostics Trial Center at Karolinska University Hospital. Other partners: Karolinska Institutet, Affibody and Akiram Therapeutics. IHE leads work package 5 developing health economic models to evaluate cost-effectiveness of theranostic interventions.
• I3LUNG Consortium PartnerscoreStrategic or Co-development Partner · 1 January 2022I3LUNG is a Horizon Europe-funded project (EUR 10 million, 5-year project) aimed at creating an AI-based clinical decision tool for personalized lung cancer treatment. The project involves 16 European and international partners including clinical cancer centers from Italy, Germany, Greece, Spain, Israel, and USA. IHE participates as the health economics partner, developing health economic models to evaluate the cost-effectiveness of AI-driven immunotherapy selection for non-small cell lung cancer patients.
• Test Bed Sweden for Precision Health in CancercoreStrategic or Co-development Partner · 1 January 2021Test Bed Sweden is a VINNOVA-funded innovation environment for clinical trials and implementation of precision health in cancer care, coordinated by Stockholm School of Economics Institute for Research. It has 15 partners from regions, academia, industry, patient organizations and authorities. IHE develops strategies for health economic analysis of precision health, determining what methods and data are needed to demonstrate value of personalized diagnostics and treatment.
• PsoReg (Nationella kvalitetsregistret för systembehandling av psoriasis)minorStrategic or Co-development Partner · 1 January 2019Long-standing collaboration with the national quality registry for psoriasis treatment (PsoReg) which has resulted in numerous publications in dermatology. IHE contributes health economic expertise and analyses based on registry data.
• Lund UniversitycoreOthersSeveral IHE employees work part-time at Lund University. IHE has close collaborations with academia and Lund University's economics department. The organization is owned through IHE Holding AB by IHE's CEO, IHE's staff and the Bengt Jönsson Foundation for Health Economic Research.
• Karolinska InstitutetcoreOthersSeveral IHE employees work part-time at Karolinska Institutet. Peter Lindgren is professor of health economics at Karolinska Institutet. IHE collaborates on academic projects with the institute, including participation in the PROMINENT consortium.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Xcenda: AmerisourceBergen's HEOR and market access consultancy. Direct peer to IHE in providing economic modelling, HTA support, and real-world evidence generation for pharma manufacturers globally.
• Evidera: Multi-disciplinary HEOR, market access and real-world evidence consulting firm (now part of Thermo Fisher's PPD). Directly comparable to IHE in offering cost-effectiveness modelling, HTA submissions and RWE studies to pharma clients globally.
• RTI Health Solutions: Health economics and outcomes research consulting division of RTI International. Closely comparable to IHE in delivering HEOR studies, economic modelling, and patient-reported outcomes research for pharmaceutical and medtech clients.
• OPEN Health (Pharmerit International): Global HEOR and market access consultancy formed around Pharmerit. Comparable to IHE in providing economic modelling, HTA submissions, and value communications for pharma across multiple therapy areas.
• Mapi Research Trust (Clinigen): Health outcomes and epidemiology consultancy (acquired by Clinigen). Highly comparable to IHE in producing real-world evidence, patient-reported outcomes research, and health economics analyses for life sciences clients.
• CBPartners: Specialist market access and health economics consultancy. Comparable to IHE in delivering HTA submissions, value strategy, and economic modelling for pharmaceutical and biotech clients, with strong oncology and rare disease overlap.

Broad incumbents

• IQVIA: Global life sciences services giant with a large HEOR and real-world evidence practice. Overlaps with IHE in cost-effectiveness modelling and RWE but operates at vastly larger scale across a broad portfolio of CRO and commercial services.
• Parexel International: Global CRO with a dedicated HEOR and market access function. Comparable to IHE in offering economic modelling and HTA support, but as part of a much broader clinical development and commercialization portfolio.

Others

• Swedish TLV (Dental and Pharmaceutical Benefits Agency): Swedish national HTA and reimbursement agency. Not a competitor but a frequent counterparty: IHE provides commissioned analyses and expert input to TLV, making it a key ecosystem participant rather than a market peer.
• Norwegian Institute of Public Health (FHI): Norwegian public health and HTA body. Comparable to IHE in producing health economic evaluations for Nordic reimbursement decisions, but as a public-sector agency rather than a commercial consultancy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/swedish-institute-for-health-economics
• Xx.com/IHE08912687

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IHE